Iambic Therapeutics | Better technology for better medicines

Better technology for better medicines

Our molecular superintelligence platform delivers differentiated drug candidates, optimized for patient and partner impact

Optimized medicines for optimized profiles

Our AI technologies, Enchant and NeuralPLexer, drive a high-throughput experimental platform that converts novel molecular designs into biological insights each week

Platform

Innovation

Multimodal transformer and co-folding AI technologies built for the purpose of drug discovery

Automation

AI-driven, high-throughput experimentation to go from new molecular designs to new biological data each week

Execution

A proprietary pipeline of differentiated clinical candidates delivered at a pace years faster than the industry standard

Platform-driven pipeline of
differentiated drug programs

We are unlocking the untapped potential of known targets and transforming seemingly undruggable targets into opportunities for breakthrough treatments

Pipeline

IAM1363 for HER2

Phase 1/1b

Selective, brain-penetrant inhibitor for HER2-driven cancers that has shown anti-tumor activity and tolerability in Phase 1/1b studies

IAM217 for KIF18A

IND-enabling

Differentiated, brain-penetrant inhibitor for ovarian cancer, triple-negative breast cancer, and other solid tumor cancers

IAM-C1 for CDK2/4

IND-enabling

Selective CDK2/4 small-molecule inhibitor for HR+/HER2- breast cancer and CCNE1 amplified cancers

Innovation through the collaboration of AI experts and drug hunters

By placing AI innovations in the hands of our seasoned drug hunters, we’re optimizing our path towards differentiated therapeutics

About us